Related Experiment Videos
Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
Amir Arastehfar1, Toni Gabaldón2,3,4, Rocio Garcia-Rubio1
1Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.
Abstract:
The high clinical mortality and economic burden posed by invasive fungal infections (IFIs), along with significant agricultural crop loss caused by various fungal species, has resulted in the widespread use of antifungal agents. Selective drug pressure, fungal attributes, and host- and drug-related factors have counteracted the efficacy of the limited systemic antifungal drugs and changed the epidemiological landscape of IFIs. Species belonging to Candida, Aspergillus, Cryptococcus, and Pneumocystis are among the fungal pathogens showing notable rates of antifungal resistance. Drug-resistant fungi from the environment are increasingly identified in clinical settings. Furthermore, we have a limited understanding of drug class-specific resistance mechanisms in emerging Candida species. The establishment of antifungal stewardship programs in both clinical and agricultural fields and the inclusion of species identification, antifungal susceptibility testing, and therapeutic drug monitoring practices in the clinic can minimize the emergence of drug-resistant fungi. New antifungal drugs featuring promising therapeutic profiles have great promise to treat drug-resistant fungi in the clinical setting. Mitigating antifungal tolerance, a prelude to the emergence of resistance, also requires the development of effective and fungal-specific adjuvants to be used in combination with systemic antifungals.
Insights
Antifungal drug resistance is increasing in invasive fungal infections (IFIs) and agriculture, driven by various factors. Strategies like stewardship programs and new drug development are crucial to combat resistant fungi.
Area of Science:
- Medical Mycology
- Antimicrobial Resistance
- Drug Discovery
Background:
- Invasive fungal infections (IFIs) cause high mortality and economic losses.
- Widespread antifungal agent use has led to increased drug resistance in fungi.
- Limited systemic antifungal drugs face challenges from fungal, host, and drug-related factors.
Purpose of the Study:
- To review the current landscape of antifungal resistance in clinical and agricultural settings.
- To discuss the mechanisms and contributing factors to antifungal resistance.
- To highlight strategies for mitigating antifungal resistance and managing IFIs.
Main Methods:
- Literature review of antifungal resistance trends.
- Analysis of factors contributing to resistance.
- Evaluation of current and future management strategies.
Main Results:
- Significant antifungal resistance observed in Candida, Aspergillus, Cryptococcus, and Pneumocystis species.
- Environmental drug-resistant fungi are increasingly found in clinical settings.
- Limited understanding of resistance mechanisms in emerging Candida species.
Conclusions:
- Antifungal stewardship programs and susceptibility testing are vital to minimize resistance.
- New antifungal drugs and adjuvants are needed to treat resistant infections.
- Addressing antifungal tolerance is key to preventing resistance emergence.
Related Concept Videos
Fungal Phylum Microsporidia
Development of Antibiotic Resistance
Fungal Group Zygomycota
Fungal Phylum Ascomycota
Treatment Resistant Cancers
Overview of Fungi